#News for #Investors and #Media: The European Commission (EC) has approved a new prefilled syringe presentation of one of our vaccines. 👉 Learn more: gsk.to/3LvBgAu

#News for #investors and #media: We’ve just announced data from our pivotal phase III clinical programmes for chronic hepatitis B (CHB). This marks an important step towards addressing the global burden of CHB. Learn more: gsk.to/49HDLZM

#News for #investors and #media: A new therapy for two respiratory diseases has received approval from Japan’s health authority. Learn more here: gsk.to/3Lm8ZfI

#News for #investors and #media: We have announced that China’s health authority has approved one of our therapies for use in adults with a respiratory disease. Learn more here: gsk.to/4jqC3PO

Happy New Year from all of us! 🎉 As we step into 2026, our commitments remain strong. We're excited to continue on our journey to get ahead of disease together. What are you looking forward to achieving in 2026?

Season’s greetings from us at GSK to you! 🎄 May your day be filled with peace, happiness and special moments shared with those closest to you ✨

From our network to yours, we’re wishing you a happy holiday season from across the globe! Dive into the festive spirit and hear directly from our manufacturing teams who ensure our vital medicines and vaccines reach patients, even during this special time of year.👇

A new therapy for a respiratory disease has received approval today from the US Food and Drug Administration (FDA). For more information, visit: gsk.to/3KOUZLg

We're leaving #ASH25 filled with even more inspiration and determination to bring innovative treatment options to patients living with challenging blood cancers. Watch to see how our team engaged at this year’s meeting! 🎥 🩸

#News for #Media and #Investors: Today, we are announcing that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new therapy to treat two respiratory diseases. For more information, visit: www.gsk.com/en-gb/

At The Washington Post Live Post Next: The Future of Cancer event, Hesham Abdullah, Global Head of Oncology R&D shared what’s inspiring our vision to advance innovative research so those living with cancer can do more of what they love with those they care about most. Watch the video bit.ly/4qcE6ZT

We’re committed to uncovering the secrets behind disease biology through a new partnership with the Teichmann Lab at the Cambridge Stem Cell Institute called the Human Cell Atlas. Click to find out how this new partnership impacts drug discovery: gsk.to/4pAUhjW

#News for #investors and #media: We’re excited to share that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of two potential biologic treatments across three respiratory conditions. Learn more: gsk.to/48MZ1M2#News

#News for #investors and #media: The European Medicines Agency’s CHMP have issued a positive opinion on the expansion to a younger population for one of our vaccines. Access our website here: gsk.to/4aLrWTg

#News for #Media and #Investors: Today, we are announcing that one of our oral anti-infectives has been approved by the FDA. Learn more: www.gsk.com#News#Media

#News for #Investors and #Media: Today we announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation to an investigational antibody-drug conjugate in our oncology pipeline. Learn more here: gsk.to/4rFbiuy

Globally, more than 1 million people are diagnosed with a blood cancer each year. Through our latest research programmes, we are innovating for patients with blood cancers to help address their unmet needs. Watch to learn more. #ASH25

Outsmarting cancer demands focus 🔍 That’s why we’re channelling our science and technology where it can make the biggest difference for people living with cancer. Catch us at #ASH25 this weekend!

Big news for U.S. innovation! We've officially opened our new Vaccine & Infectious Disease R&D HQ in Boston's Cambridge Park Drive. This expanded space is central to our 5-year investment in the U.S., driving faster, better innovation for patients globally.

We’re looking forward to being on the ground at #ASH25 this weekend, presenting our latest progress in blood cancer research. What are you most excited for during this year’s congress? 👇

#News for #investors and #media: We are pleased to present new data from our #bloodcancer pipeline and portfolio at #ASH25. Learn more: gsk.to/4oKX2xX#News

2000 ➡️ 2025: celebrating 25 years of partnership with the @who.int on the Global Programme to Eliminate Lymphatic Filariasis (GPELF). 🔗 Find out more about the impact of the GPELF, here: gsk.to/4iwJ2X4

“More years in life, and more life in those years." That's what drives our research for people living with multiple myeloma 🧡 Our GSK experts explore what multiple myeloma is, the challenges patients face, and the potential impact of our research. 🎥 Watch the conversation: bit.ly/4rfYhaC

For Covid-19 and influenza, the risks are well-known but many people underestimate respiratory syncytial virus, or RSV. 🔗 Find out who is most at risk and how they can protect themselves: gsk.to/4icL4eL

80 years after the Nobel Prize for penicillin, antimicrobial resistance is one of societies toughest challenges. GSK, the Fleming Initiative, and the @ineosoxford.bsky.social hosted leaders at the Royal Society of Medicine to advance the global response.

Every day infections are becoming harder to treat. The solutions exist. The challenge is acting fast enough, together, to make them count. Hear from experts from across science and healthcare on how we can get ahead of AMR if we act together, now.

COPD affects over 390 million people globally, significantly impacting patients like Val and their families. This #WorldCOPDDay2025 highlights the urgent need for earlier intervention to improve lives.

We’re announcing a major research programme with the Fleming Initiative to find new ways to get ahead of #AMR. We’re combining scientific expertise with cutting-edge AI technology, including funding for around 50 dedicated UK scientific and academic positions: gsk.to/4r4CrqD

Living with blood cancer often means lifelong treatment, frequent hospital visits, and managing challenging side effects. But what if there are more ways to improve both care and quality of life? 🔗 Read more: bit.ly/43z2Brb

We’re proud to join industry leaders and key policymakers at the #SilverEconomyForum in Manchester to discuss how we can foster trust in science to get ahead of disease and build more resilient societies. Watch this video to learn more about our approach to unlocking the power of prevention 👇

#News for #investors and #media: At #TLM25 we’ll share new data from our advancing hepatology pipeline - with 21 abstracts covering CHB, MASH, ALD and PBC. We remain committed to addressing the global burden of liver disease. Learn more: gsk.to/3WJNqIa#News

Join us at the American Society of Nephrology congress this week, as we partner with nephrology leaders to talk about the importance of protecting kidney function and supporting long-term health outcomes for people living with lupus.

"One person doesn’t make a difference. We all come together, and we make it happen.” From facing cancer to co-founding the Multiple Myeloma Research Foundation, Kathy Giusti has made a huge difference to the lives of so many living with cancer. 🎥 Watch more: gsk.to/4nfiSJ7

Today we announce our Q3 2025 results, with another quarter of strong performance and upgraded guidance for 2025. Hear more from our CEO Emma Walmsley ⤵️ More information for media and investors: gsk.com $GSK #Q3Results

#News for #investors and #media: Today we announced an agreement with Empirico to add to our pipeline in COPD and potentially other inflammatory respiratory diseases. Find out more: gsk.to/4oF5Vt6

#News for #Investors and #Media: Today we announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to an investigational antibody-drug conjugate in our oncology pipeline. Learn more here: gsk.to/4hwnHfz

#News for #investors and #media: Today we announced an agreement with Syndivia to add to our growing oncology pipeline in prostate cancer. Find out more: gsk.to/4nrTYFX

#News for #Investors and #Media The US Food and Drug Administration (FDA) has approved our therapy to treat an incurable and challenging blood cancer. For more information, visit: www.gsk.com#News

“Our patients - including families just like mine - are relying on us. We won't let them down.” In this article, Hesham Abdullah shares his family's story and how his team are working tirelessly to realise a future where people don't just survive cancer but thrive long after. 🔗bit.ly/4o9ASpq

We’re at #IDWeek2025 because infectious diseases remain one of the greatest public health challenges, responsible for one in six deaths worldwide. Many are still overlooked, and rising resistance is making treatment options less effective. ➡️ Want to learn more? www.gsk.com/en-gb/innova...

#News for #investors and #media: We’ve just announced data from our pivotal phase III clinical programme for a metered dose inhaler (MDI): gsk.to/4nkQipr

Together with ViiV Healthcare, we’re investing a total of £6m in the Global Fund, to help them fund locally led programmes that are tackling the high burden of HIV, tuberculosis and malaria in lower income countries.

#News for #Investors and #Media: The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for a new prefilled syringe presentation of one of our vaccines. Learn more: gsk.to/47egZpR

#News for #Media and #Investors: Today, with Spero, we are sharing an update on the Phase III trial results of one of our investigational oral anti-infectives, presented during #IDWeek2025 in Atlanta. Learn more: gsk.to/47h8tGN#News

“It’s hard to explain the pain of a UTI to people who’ve never had one.” 🔗 Read LeAnn’s story and why she thinks personalised care is so important: gsk.to/4hkD8aO #IDWeek2025

Modern medicine has revolutionised the way we live but the challenges to our health are evolving. Find out why preventing disease is the best investment not just for people but also for the world’s health systems, societies and economies 👇 #IDWeek2025

Understanding the challenges faced by those living with gynaecologic cancers is key to driving change. Visit us at #ESMO25 to learn more about our Your Cancer Is Our Challenge survey and how we’re working to amplify patient voices and improve care. 🔗 Learn more: bit.ly/4h9h2YB

Globally, one in five people will be diagnosed with cancer in their lifetime. We’re working to change outcomes for patients facing that reality. By advancing innovative oncology research, we’re aiming to redefine what’s possible in cancer care. ➡️ Find us at #ESMO25 this week to learn more.

Evolving health threats demand focus on prevention. At the #WorldHealthSummit, we discussed the need to work together to help preventative interventions reach people who need them. Prioritising prevention can transform lives, protect global health & boost economies: gsk.to/3W4Etc2#WorldHealthSummit

Great discussion with @statnews.com and @matthewherper.bsky.social at the 2025 #StatSummit. Emma highlighted our strong investment in the US, focus on preventative healthcare, and how AI is reshaping our business.